By analyzing the expression of HER-2 and Topo II-α in breast cancer, we found that the overexpression of HER-2 and amplification of TopoII-α were related to the poor prognosis of LRCB, and the sensitivity of these patients to anthracycline-containing drug regimens increased [15, 16]. Here, ERBB2 is linked to breast carcinoma.